Oct 23, 2023
|
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
|
Oct 18, 2023
|
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
|
Oct 17, 2023
|
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
|
Oct 17, 2023
|
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
|
Oct 13, 2023
|
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
|
Oct 4, 2023
|
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
|
Sep 28, 2023
|
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
|
Sep 25, 2023
|
Tenapanor for Hyperphosphatemia Approved in Japan
|
Sep 11, 2023
|
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
|
Sep 8, 2023
|
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
|